Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors

Young Shin Cho, Hayley C. Angove, Christopher T. Brain, Christine Hiu-Tung Chen, Hong Cheng, R.k. Cheng, Rajiv Chopra, Kristy Chung, Miles Congreve, Claudio Dagostin, Deborah Davis, Ruth E. Feltell, J. Giraldes, Steven D. Hiscock, Sunkyu Kim, Steven Kovats, Bharat Lagu, Kim Lewry, Alice Loo, Yipin Lu, Michael J. Luzzio, Wiesia Maniara, Rachel McMenamin, Paul N. Mortenson, Rajdeep K. Benning, Marc O’Reilly, David C. Rees, Junqing Shen, Troy Smith, Yaping Wang, Glyn Williams, Alison J.‐a. Woolford, Wojciech Wrona, Mei Ying Xu, Fan Yang, Steven HowardACS 2012 · DOI

TL;DR

Researchers have developed a new class of highly selective CDK4/6 inhibitors, starting from a small fragment and using structure-guided design. The lead compound, 6, shows potent inhibition of CDK4/6, excellent selectivity over other CDKs, and demonstrates oral efficacy in preclinical cancer models, offering a promising therapeutic avenue.

What Problem Does This Paper Address?

The paper addresses the critical need for targeted cancer therapies by focusing on the dysregulation of cell cycle progression, a hallmark of cancer. Specifically, it targets Cyclin-Dependent Kinases 4 and 6 (CDK4/6), which play a crucial role in driving cells from the G1 phase to the S phase of the cell cycle. In many cancers, particularly breast cancer, CDK4/6 activity is abnormally high, leading to uncontrolled cell proliferation. While general CDK inhibitors exist, they often have significant side effects due to their broad activity. The challenge is to develop inhibitors that are highly selective for CDK4/6, thereby minimizing off-target effects and offering a wider therapeutic window. This selectivity is particularly important because CDK1 can compensate for CDK4/6 loss, suggesting that selective CDK4/6 inhibition might be tolerated better than pan-CDK inhibition.

Methods

The discovery and optimization process employed a fragment-based drug discovery (FBDD) approach. This began with a small molecule fragment (Fragment A) identified through screening that weakly inhibited CDK6. Key techniques included:

  • X-ray Crystallography: Used extensively to determine the binding mode of fragments and subsequent inhibitors within the ATP-binding pocket of CDK6. This provided crucial structural information for guiding rational drug design.
  • Structure-Guided Optimization: Iterative design of new compounds based on the insights gained from crystallography. This involved systematically modifying the fragment to improve potency, selectivity, and pharmacokinetic properties.
  • Enzymatic Assays: Standard biochemical assays were used to measure the inhibitory potency (IC50 values) of compounds against CDK4/6 and other related kinases (CDK1, CDK2).
  • Cellular Assays: Assessed the ability of compounds to inhibit retinoblastoma protein (pRb) phosphorylation in cancer cell lines (Jeko-1), a direct downstream effect of CDK4/6 inhibition.
  • Pharmacokinetic (PK) Studies: Evaluated drug absorption, distribution, metabolism, and excretion in preclinical models (rats) to assess oral bioavailability and clearance.
  • In Vivo Xenograft Models: Tested the efficacy of the lead compound in mice bearing human Jeko-1 mantle cell lymphoma tumors, measuring tumor growth inhibition and pharmacodynamic effects (pRb phosphorylation).
  • Docking Studies: Computational modeling (GOLD-based software) was used to predict binding modes and guide further structural modifications.

Datasets

  • CDK Enzyme Assays: Data from enzymatic assays measuring IC50 values for compounds against CDK1, CDK2, CDK4, and CDK6.
  • Cellular Assays: Data from Jeko-1 cell line assays measuring cellular IC50 values for pRb phosphorylation inhibition.
  • In Vivo PK Data: Pharmacokinetic parameters (e.g., plasma clearance, AUC) obtained from rat studies.
  • In Vivo Efficacy Data: Tumor volume measurements and pRb phosphorylation inhibition data from Jeko-1 xenograft mouse models.
  • Supporting Information: Detailed enzyme assay conditions, cellular assay conditions, FACS conditions, crystallography conditions, in vivo experimental methods, synthetic procedures, characterization data for compounds, and further PK data.

Key Insights and Ideas

  • Fragment-Based Approach is Effective: Starting with a weak fragment and iteratively optimizing it based on structural information proved to be a successful strategy for discovering potent and selective inhibitors.
  • Structural Determinants of Selectivity: The crystal structures revealed specific interactions within the CDK6 ATP pocket, highlighting residues like Lys43 and His100 as key targets for achieving selectivity over CDK1/2. Differences in these residues between CDK4/6 and CDK1/2 were exploited.
  • Exploiting the Gatekeeper Residue: Modifications were designed to interact favorably with CDK6's gatekeeper residue (Phe98) while potentially causing steric or electrostatic clashes with the corresponding residue in CDK1/2.
  • 7-Azabenzimidazole as a Key Scaffold: Introducing the 7-azabenzimidazole moiety was a critical step in significantly improving selectivity over CDK1/2, likely by optimizing interactions with His100.
  • Balancing Potency and Pharmacokinetics: The optimization process involved a trade-off between biochemical potency and pharmacokinetic properties. For instance, the trimethylpyrazole analogue (5) showed improved PK but reduced potency compared to earlier compounds.
  • Oral Bioavailability is Achievable: The lead compound (6) demonstrated good oral bioavailability and efficacy in vivo, a crucial requirement for a viable therapeutic.

Key Results

  • Compound 6: The lead compound identified, 6, demonstrated potent inhibition of CDK4 (IC50 = 0.015 µM) and CDK6 (IC50 = 0.12 µM).
  • High Selectivity: Compound 6 exhibited >1000-fold selectivity for CDK4 over CDK1 and CDK2 in enzymatic assays. It was also selective over a panel of 35 other kinases.
  • Cellular Efficacy: Compound 6 achieved a normalized cellular IC50 of 0.26 µM in Jeko-1 cells, effectively inhibiting pRb phosphorylation and inducing G1 cell cycle arrest.
  • In Vivo Efficacy: In Jeko-1 xenograft models, compound 6 showed dose-dependent tumor growth inhibition, with a dose of 250 mg/kg/day BID resulting in a 4% T/C ratio (significant tumor growth blockade).
  • Oral Bioavailability: Compound 6 achieved an oral bioavailability of 26% in rats.

Limitations and Future Work

  • Fragment Efficiency vs. Potency: While compound 6 is highly potent and selective, its ligand efficiency (LE) is lower than the initial fragment, indicating that significant structural changes were made to achieve the desired properties.
  • MTD Range: The maximum tolerated dose (MTD) was determined to be between 200 and 400 mg/kg/day bid, suggesting that higher doses might lead to toxicity, although the efficacious dose of 250 mg/kg/day was well tolerated.
  • Further Optimization: While compound 6 is a promising candidate, further optimization might be explored to potentially improve oral bioavailability, reduce clearance, or further enhance selectivity.
  • Broader In Vivo Studies: The paper focuses on a single xenograft model. Future work would involve testing compound 6 in a wider range of cancer models and potentially in combination therapies.
  • Human Clinical Trials: The ultimate validation of this compound would be its performance in human clinical trials.

Summary updated

Abstract

Herein, we describe the discovery of potent and highly selective inhibitors of both CDK4 and CDK6 via structure-guided optimization of a fragment-based screening hit. CDK6 X-ray crystallography and pharmacokinetic data steered efforts in identifying compound 6, which showed >1000-fold selectivity for CDK4 over CDKs 1 and 2 in an enzymatic assay. Furthermore, 6 demonstrated in vivo inhibition of pRb-phosphorylation and oral efficacy in a Jeko-1 mouse xenograft model.
BibTeX
@inproceedings{cho2012fragment,
  author = {Young Shin Cho and Hayley C. Angove and Christopher T. Brain and Christine Hiu-Tung Chen and Hong Cheng and R.K. Cheng and Rajiv Chopra and Kristy Chung and Miles Congreve and Claudio Dagostin and Deborah Davis and Ruth E. Feltell and J. Giraldes and Steven D. Hiscock and Sunkyu Kim and Steven Kovats and Bharat Lagu and Kim Lewry and Alice Loo and Yipin Lu and Michael J. Luzzio and Wiesia Maniara and Rachel McMenamin and Paul N. Mortenson and Rajdeep K. Benning and Marc O’Reilly and David C. Rees and Junqing Shen and Troy Smith and Yaping Wang and Glyn Williams and Alison J.‐A. Woolford and Wojciech Wrona and Mei Ying Xu and Fan Yang and Steven Howard},
  title = {{Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors}},
  booktitle = {ACS},
  year = {2012},
  doi = {10.1021/ml200241a},
}
Figure